

Market Comment | The ECB surprised markets, while the Fed remained on track

Global Financial Markets Unit 15 Jun 2018

- The monetary policy meetings, the geopolitical events (North Korea-US meeting) and trade tensions were the main highlights driving financial markets during the week.
- The FOMC increased the target range for federal funds to 2.0% and the median projections of the FOMC for year-end 2018 increased to two rate increases from one previously. The FOMC expects economic conditions to remain solid and inflation to be near 2% over the medium term. The GDP projections increased slightly in 2018 while inflation expectations were revised up. We maintain our baseline scenario of two additional rate increases in 2018. After the FOMC meeting, the market implied probability of two additional interest rate hikes increased to 50%. The release of strong US CPI growth figures (see) early this week also supported the FOMC economic outlook.
- Mild reaction in financial markets to the fresh news from the FOMC as the rate hike was priced in financial markets. 10Y Treasury yields remained hovering around 3%. Nonetheless, trade tensions returned to the forefront today (and odds of a trade war increased) as the US approved US\$50 billion of tariffs on imports of goods from China (see), which weighed on bond and equity markets.
- At yesterday's meeting, the ECB unveiled more details of its monetary normalization process. The central bank decided to extend the asset purchase programme until December 2018 but at a monthly pace of €15 billion. Regarding standard measures, key interest rates were left unchanged, as expected, while the ECB strengthened its forward guidance on rates and announced "the key ECB interest rates to remain at their present levels at least through the summer of 2019". The updated EZ GDP growth forecasts are weaker in 2018 due to the first quarter slowdown but remain unchanged in 2019-20. Changes in oil prices and the exchange rate led the ECB to revise its headline inflation forecasts considerably upwards, while core inflation has also been revised slightly upwards (see BBVA Research report).
- Eurozone markets reacted abruptly given that the ECB decisions were read as dovish by financial markets. Sharp EUR depreciation and drop in Eurozone 10Y yields after the meeting. Bund returned below 0.40% threshold and the EUR stood at 1.15 against the USD hours after the meeting. Meanwhile peripheral risk premia remaining almost unchanged, with little differentiation between Spain and Italy. European equity indices showed a positive performance, particularly those that benefited more from the EUR depreciation, such as the DAX.
- The outcome of the long-awaited meeting between North Korea and the US had a mild effect on financial markets despite the signing of an agreement seeking the complete denuclearisation of the Korean peninsula (see).



• The Japanese yen depreciated against the USD despite the BoJ meeting (see) while EM currencies depreciated across the board against the USD during the week despite the fact that the Fed's hike was almost fully priced before the meeting. After a week of relative calm, the Argentinian peso and the Turkish lira felt the market's pressure again.

Tabe1 Update 17:50 CET 15 June



		anges in I	op)	No. of Contrast	
US (2·yr) US	2.55 2.92	-1.0 -1.8	5.6 -2.9	-3 -18	63 45
GER (2-yr) Germany	-0.62 0.40	0.6	3.3 -4.5	-4 -20	-1 -6
France Spain	0.73 1.30	-3.3 -5.4	-8.4 -17.5	-11 -12	-9 -32
Italy Portugal	2.61 1.82	-13.2 -9.5	-5 2.6 -2 3.6	49 1 13	51 -19
Greece Japan (2-yr)	4.50 -0.13	-9.7 -0.1	-20.6 -1.0 -1.9	13	39 0
Japan Emerging Markets	0.04 level	-0.9 Daily	Weekly	Monthly	YTO
Brazil Chile Colombia	12.03 4.60	-27.9 0.2 4.6	39.1 4.5	184 10 4	178 9 19
Mexico	6.63 7.99 5.40	4.0	5.8 15.8	24	42
Peru Poland	3.25 7.84	5.0 2.9 15.9	-6.2	25 -2 37	53 -6
Russia Turkey	7.84 15.64 7.89	0.0	20.4 115.0	151	21 428
India Indonesia	7.30	0.0	-5.6 0.0	-1 8	100
	risk (bp, chang level	es in bp) Daily	Weekly	Monthly	YTO
10-yr sovereign spread vs Germany	33	-1.1	-3.9	9	4
Italy Portugal	220 142	-11.0 -7.3 -3.2	-48.1 -19.1	69 22	57 -13
Spain 2-yr sovereign spread vs Germany	89	-3.2	43.0	9	-26
France Italy	12 128	-12.2	-3.0 -107.3	1 62	-5 91
Portugal Spain	49 39	-12.2 -3.1 -4.2	-107.3 -18.2 -4.5	-14 11	-18 12
Emerging Markets 5-vr sovereign CDS *	level	Daily	Weekly	Monthly	YTO
Brazil	269	8.5	14	78	109
Chile Colombia	57 127	1.5 5.0	7	0 15	8 22
Argentina Mexico	410 149	28.8 2.4	53	30 26	172 42
Peru Poland	90 68	2.2 -0.4	4	5 14	18 20
Russia Turkey	140 300	-1.1	8	6 41	23 139
China	55 88	-0.6 0.5	0	-4 5	5
Indonesia	127 Risk indicators	-0.3	2	7	42
Volatilty indicators (change in pp)	level	Daily	Weekly	Monthly	YTO
VIX VSTOXX	13 12	0.4	-3	-1	-1
EM EFT volatility Index Dollar/euro volatility	18	0.3	0	0	2
EM FX volatility index Credit spread (BAA) (change in bps)	7 10 190	0.1 1.8	0	1 11	2
Credit spread (BAA) (change in bps) US bonds volatility index Inflation expectations (%)	190 52 level	1.8 -1.3 Daily	-7 Weekly	-3 Monthly	3
US Inflation expectations (5Y5Y) EZ Inflation expectations (5Y5Y)	2.44	-	0 -1	-2 0	12
Banking Sy CDS (bps) *	level	Daily	Weeldy	Monthly	
US EZ	54 86	-1.1 -5.7	-4 -13	2 31	12 47
UK Large Spanish	52 77	-2.2 -5.7	-3 -15	10 28	11 41
Medium Spanish	100	4.3 Daily	2 Wooldy	29	25 YTD
US Non-financial EZ Non-financial	144 79	-1.1 -5.7	-4 -13	2 31	12 47
UK Non-financial	107	-1.5	0	3	14
Interbank r	level	nges in b Daily	Weekly	Monthly	YTO
EONIA Index Eurlbor 3m Eurlbor 12m	-0.36 -0.32	0	-1 0	1	1
Euribor 12 m Libor 3 m	-0.18 2.33	-1	0	1	0 64
Libor 12m	2.77	0	2	2	66
Main indices	ock markets ((a) Daily	Weeldy	Monthly	YTO
S&P500 Dow Jones	2,768 24,927	-0.5 -1.0	-0.4 -1.5	1.7 0.6	3
Nikei FTSE 100	22,852 7,649	0.5	0.7	0.6	0
EuroStoxx 50	3.508	-0.5	1.8	4.5	- 1
DAX	9,870 13,019	-0.9 -0.7	1.3 2.0	-2.4 0.2	-2 1
CAC MIB	5,508 22,242	-0.4 -1.1	1.1 4.2	4.1 6.3	4
ASE Athens MSCI Latam*					
MSCI Latam*	763 81,598	-2.0 -0.4	-1.2 -0.9	-3.1 -10.0	-7 -5
Ibovespa (Brazil)	763 81,598 70,531 46,686	-0.4 -1.2 -1.1	-0.9 -3.3 1.6	-10.0 -18.5 0.6	-5 -9 -7
Ibovespa (Brazil) Mexbol (Mexico) Merval (Argentina) MSCI EM Europe *	763 81,598 70,531 46,686 30,147 5,260	-0.4 -1.2 -1.1 -0.1 -0.1	-0.9 -3.3 1.6 -4.1 -2.5	-10.0 -18.5 0.6 -4.8 -4.0	-5 -9 -7 -3 -2
Ibovespa (Brazil) Mexbol (Mexico) Merval (Argentina) MSCI EM Europe * Poland Microx 1.0 (Russia)	763 81,598 70,531 46,686 30,147 5,260 2,203 4,313	-0.4 -1.2 -1.1 -0.1 -0.1 -1.6 -0.8	-0.9 -3.3 1.6 -4.1	-10.0 -18.5 0.6 -4.8 -4.0 -3.2 -5.2	-5 -9 -7 -3 -2 -10 5
Ibovespa (Brazil) Mexbol (Mexico) Merval (Argentina) MSCI EM Europe * Poland Microx 1.0 (Russia)	763 81,598 70,531 46,686 30,147 5,260 2,203	-0.4 -1.2 -1.1 -0.1 -0.1 -1.6	-0.9 -3.3 1.6 -4.1 -2.5 -2.1	-10.0 -18.5 0.6 -4.8 -4.0 -3.2 -5.2 -7.5	-5 -9 -7 -3 -2 -10 5
lbovespa (Brazil) Mechol (Mesico) Merval (Argentina) MSCI EM Europe * Poland Micse 10 (Russia) Joe 100 (Turkey) MSCI EM Asia * MSCI EM Asia *	763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 3,022	-0.4 -1.2 -1.1 -0.1 -1.6 -0.8 -0.0 -0.9 -0.7	-0.9 -3.3 1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5	-10.0 -18.5 -0.6 -4.8 -4.0 -3.2 -5.2 -7.5 -0.1 -4.7	-5 -9 -7 -3 -2 -10 5 -20 2
Ibovepse (Brazil) Mervid (Argentina) Mervid (Argentina) Micce 10 (Russia) Bes 100. (Turkey) MSCI EM Asia * Shanghai Com (China) Jalanta (Indionesia) Banking isector.	763 81.598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 3,022 5,994	-0.4 -1.2 -1.1 -0.1 -0.1 -1.6 -0.8 -0.0 -0.9 -0.7 -0.0 -0.0	-0.9 -3.3 1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9 Weekly	-10.0 -18.5 0.6 -4.8 -4.0 -3.2 -5.2 -7.5 -0.1 -4.7 2.7	-5 -9 -7 -3 -2 -10 5 -20 2 -10 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7
Illowensa (Emzil) Mexhol (Mexho) Mexhol (Mexhol) Mexhol	763 81.598 70.531 46.686 30.147 5.260 2.203 4.313 94.541 936 3.022 5,994 level	-0.4 -1.2 -1.1 -0.1 -0.6 -0.8 -0.0 -0.9 -0.7 -0.0 -0.9 -1.2 -1.2	-0.9 -3.3 1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9	-10.0 -18.5 -0.6 -4.8 -4.0 -3.2 -5.2 -7.5 -0.1 -4.7 -2.7 Monthly -6.6 -5.8	-5 -9 -7 -3 -2 -10 5 -20 2 -10 -6 YTD -5 -1
Iboverpa (Brazil) Mewbol (Mewbo) Mewbol (Meybo) Mewbol (Meybo) Mewbol (Meybo) Mewbol (Meybo) Mewbol (Mewbo) Mewbo) Mewbol (Mewbo) Mewbo)	763 81.598 70.531 46.686 30.147 5.260 2.203 4.313 94.541 936 3.022 5.994 140.8 106.8 65.7 29.0	-0.4 -1.2 -1.1 -0.1 -0.6 -0.8 -0.0 -0.9 -0.7 -0.0 Daily -1.2 -1.2 -0.7 -1.6	-0.9 -3.3 1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9	-10.0 -18.5 0.6 4.8 4.0 -3.2 -5.2 -7.5 -0.1 4.7 2.7 Monthly -6.6 -6.8 -8.7 -6.5	-5 -9 -7 -3 -2 -10 5 -20 2 -10 -6 YTO -5
Illowers (Bazel) Weekol (Mexico) Weekol (Mexic	763 81.598 70.531 46.686 30.147 5.260 2.203 4.313 94.541 936 3.022 5.994 104.8 106.8 65.7 29.0 50.8	-0.4 -1.2 -1.1 -0.1 -0.6 -0.8 -0.0 -0.9 -0.7 -0.0 Daily -1.2 -1.2 -0.7 -1.6	0.9 -3.3 1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9	-10.0 -18.5 0.6 4.8 4.0 -3.2 -5.2 -7.5 -0.1 4.7 2.7 Monthly -6.6 -5.8 -8.7 -6.5 -7.6 -4.5	-5 -9 -7 -3 -2 -10 5 -20 2 -10 -6 YTC -5 -1 -12 -3 -3
horeque (Hazel) Meteral Disposition Merral Disposition Merral Disposition Merral Disposition Micra 10 Granisa Micr	763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 3,022 5,994 140,8 106,8 65,7 29,0 50,8 230,1 91,8 54,1	-0.4 -1.2 -1.1 -0.1 -1.6 -0.8 -0.9 -0.7 -0.0 Daily -1.2 -1.2 -1.2 -1.6 -1.6 -1.5 -1.5	0.9 -3.3 1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9	-10.0 -18.5 0.6 4.8 4.0 -3.2 -5.2 -7.5 -0.1 4.7 2.7 Monthly 6.6 -5.8 8.7 -6.5 -7.6 -4.5 -7.6 -4.5 -7.6 -4.5 -7.6 -4.5 -7.6 -4.5 -7.6 -4.5 -7.6 -4.5 -7.6 -4.5 -7.6 -4.5 -7.6 -7	-5 -9 -9 -7 -3 -3 -2 -100 -5 -200 -2 -100 -5 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1
horeeper (Heart) Medical (Medical Medical Med	763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 3,022 5,994 140,8 106,8 65,7 29,0 50,8 230,1 91,8 54,1 11,8	-0.4 -1.2 -1.1 -0.1 -1.6 -0.8 -0.0 -0.9 -0.7 -1.2 -0.7 -1.6 -1.0 -1.5	0.9 -3.3 1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9 Weekly -3.1 -3.9 -4.0 -3.3 -2.2 -1.4 0.9	-10.0 -18.5 0.6 -4.8 -4.0 -3.2 -5.2 -7.5 -0.1 -4.7 -2.7 	-5 -9 -9 -7 -3 -3 -2 -100 -5 -5 -1 -1 -12 -3 -3 -10 -166 -166 -166 -166 -166 -166 -166
horeque (Hazel) Medical (Medical) Mercal (Medical) Mercal (Medical) Mercal (Medical) Mercal (Medical) Medical (Medical)	763 81.598 70.531 46.885 30.147 5.260 2.203 4.313 94.541 1936 3.022 5.994 140.8 65.7 29.0 50.8 230.1 11.8 91.8 54.1 11.8	-0.4 -1.2 -1.1 -0.1 -0.6 -0.8 -0.9 -0.7 -0.0 -0.9 -1.2 -1.2 -0.7 -1.6 -1.0 -1.5 -1.5 -1.3 -1.9 -1.7 -1.3	0.9 -3.3 -1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9 -2.1 -3.1 -3.9 -4.0 -3.3 -2.2 -1.4 0.9 0.8 -0.5 -0.8	-10.0 -18.5 -0.6 -4.8 -4.0 -3.2 -7.5 -0.1 -4.7 -2.7 Monthly -6.6 -5.8 -8.7 -6.5 -7.6 -4.5 -7.6 -4.5 -12.7 -13.1 -12.4 -13.5 -5.6	-5 -9 -9 -7 -3 -3 -2 -2 -100 -5 -2 -2 -100 -6 -6 -7 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10
horeage (Marcil Medical (Marci	763 81.598 70.531 46.686 30.147 5.260 2.203 4.313 94.541 936 3.022 5.994 140.8 106.8 65.7 29.0 50.8 230.1 11.8 95.2 11.8 11.8 95.2 11.8 11.8 95.2 11.8 11.8 95.2 11.8 11.8 95.2 11.8 11.8 11.8 95.2 11.8 11.8 11.8 11.8 11.8 11.8 11.8 11	-0.4 -1.2 -0.1 -0.6 -0.8 -0.0 -0.9 -0.7 -0.0 -0.9 -0.7 -1.2 -1.2 -1.2 -1.5 -1.5 -1.5 -1.3 -1.9 -1.7 -1.3 -1.7 -1.3 -1.3 -1.3 -1.3 -1.3 -1.3 -1.3 -1.3	0.9 -3.3 -1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9 -3.1 -3.9 -4.0 -3.3 -2.2 -1.4 -0.9 -0.8 -0.6 -0.8 -0.8	-10.0 -18.5 -0.6 -4.8 -4.0 -3.2 -5.2 -7.5 -0.1 -4.7 -2.7 -6.6 -5.8 -8.7 -6.5 -7.6 -4.5 -7.6 -4.5 -12.7 -13.1 -12.7 -13.1 -12.7 -13.5 -17.8 -17.8 -17.8	-5 -9 -9 -7 -3 -3 -2 -2 -100 -5 -5 -11 -12 -3 -3 -15 -411 -188 -7 -144
horeage (Mazel) Medeol (Medeol) Merel (Degregation) Merel (Degregation) Merel (Degregation) Medeol (Medeol) Medeol (Medool) Medool (Medool) Me	763 81.598 70.531 46.686 30.147 5.260 2.203 4.313 94.541 936 65.7 29.0 50.8 230.1 140.8 150.8 51.8 54.1 11.8 91.8 54.4 91.8 50.8 65.7 29.0 50.8 230.1 11.8 91.8 54.4 91.8 91.8 91.8 91.8 91.8 91.8 91.8 91.8	0.4 1.2 0.1 0.1 1.6 0.8 0.0 0.9 0.7 0.0 0.0 1.2 1.2 1.2 1.5 1.5 1.5 1.5 1.5 1.5 1.5	0.9 -3.3 -1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.9 -2.1 -1.9 -2.1 -1.9 -2.1 -3.9 -4.0 -3.3 -2.2 -1.4 -0.9 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.1 -0.8 -0.6 -0.8 -0.1 -0.8 -0.6 -0.8 -0.1 -0.8 -0.6 -0.8 -0.1 -0.8 -0.1 -0.8 -0.1 -0.8 -0.1 -0.8 -0.8 -0.8 -0.8 -0.8 -0.8 -0.8 -0.8	-10.0 -18.5 0.6 4.8 4.0 3.2 5.2 7.5 -0.1 4.7 2.7 Monthly 6.6 5.8 8.7 6.5 -7.6 5.8 4.5 -12.7 -13.1 -12.4 -13.5 -5.6 -17.8 -17	-5 -9 -9 -7 -7 -3 -2 -2 -100 -5 -5 -1 -1 -12 -3 -3 -10 -16 -13 -15 -15 -1 -18 -7 -14 -18 -9 -6 -6
horeage (March Moreage M	763 81.598 70.531 46.686 30.147 5.260 2.203 4.354 1936 3.022 5.994 140.8 200.1 91.8 91.8 91.6 140.8 230.1 91.8 95.6 140.8 230.1 91.8 95.6 140.8 240.1 95.6 95.6 95.6 95.6 95.6 95.6 95.6 95.6	0.4 1.2 0.1 0.1 0.1 1.6 0.8 0.0 0.7 0.0 0.7 0.0 1.2 1.2 0.7 1.6 1.5 1.3 1.9 1.7 1.3 1.8 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	0.9 3.3 1.6 4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9 Weekly -3.1 -3.9 -4.0 -3.3 -2.2 -1.4 -0.9 0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.1 -0.9 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.6 -0.8 -0.9 -0.9 -0.9 -0.9 -0.9 -0.9 -0.9 -0.9	-10.0 -18.5 -0.6 -4.8 -4.0 -3.2 -5.2 -7.5 -0.1 -4.7 -2.7 -6.5 -7.6 -5.8 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5	-5 -9 -9 -7 -7 -3 -2 -2 -100 -5 -5 -1 -1 -12 -3 -3 -15 -41 -1 -18 -9 -6 -6 -8 -8 -8
horeque (Marcil Medical (Medical) Medical (Medic	763 81.598 70.531 46.686 30.147 5.260 2.203 4.313 94.541 936 30.022 5.994 140.8 200.1 91.8 95.9 140.8 230.1 91.8 95.5 91.8 95.5 94.1 11.8 95.5 95.5 95.6 95.6 95.6 95.6 95.6 95.6	0.4 1.2 1.1 0.1 1.6 0.8 0.0 0.9 0.7 1.2 0.7 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	0.99 3.3 1.5 4.1 1.6 4.1 1.8 4.1 1.8 4.8 1.5 1.9 4.0 1.9 4.0 0.9 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8	-10.0 -18.5 -0.6 -4.8 -4.0 -3.2 -5.2 -7.5 -0.1 -4.7 -2.7 Monthly -6.5 -8.8 -7.5 -12.7 -13.1 -12.4 -13.5 -12.7 -17.8 -17.	-5 -9 -9 -7 -7 -3 -3 -2 -100 -5 -5 -200 -2 -100 -5 -1 -12 -3 -3 -15 -100 -166 -41 -418 -9 -6 -6 -8 -8 -4 -8 -8
horeque (Marcil More) Mercal (Marcil More) Mercal (Marcil More) More (Marcil More)	763 81.598 70.531 46.686 30.147 5.260 2.203 94.541 140.8 106.8 106.8 106.8 108	0.4 1.2 1.1 0.1 1.6 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.7 1.6 1.0 1.1 1.0 1.1 1.0 1.1 1.0 1.1 1.0 1.1 1.0 1.1 1.0 1.0	0.99 3.3 1.6 4.1 4.1 4.1 4.1 4.1 4.8 4.1.5 4.9 4.0 3.1 4.0 3.3 4.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6	-10.0 -18.5 -0.6 -4.8 -4.0 -3.2 -5.2 -7.5 -0.1 -4.7 -2.7 -4.7 -6.5 -7.6 -5.8 -8.7 -6.5 -7.6 -12.1 -13.1 -12.4 -13.5 -12.4 -13.5 -12.4 -13.6 -13.	-5 -9 -9 -7 -7 -3 -2 -2 -100 -5 -2 -2 -100 -5 -11 -12 -3 -3 -100 -16 -13 -15 -14 -18 -9 -6 -6 -6 -8 -8 -4 -4 -8 -15 -114 -18
horeque (Mazel) Meteral Organization Meteral Margineristics Meteral Margineristics Meteral Margineristics Meteral Margineristics Meteral Organization Metera	763 81.598 70.531 46.586 30.147 5.260 2.203 94.581 140.8 160	0.4 1.2 1.1 0.1 1.6 0.0 0.0 0.0 0.7 0.0 0.7 0.0 1.2 1.2 1.2 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	0.99 3.3 3.1.6 4.1.1 4.1.1 2.5 2.1 1.8 1.8 1.5 1.9 4.0 3.1 3.1 3.9 4.0 0.8 0.8 5.1 0.8 0.8 5.2 2.1 1.0 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0	-10.0 -18.5 -0.6 -4.8 -4.0 -3.2 -7.5 -0.1 -4.7 -2.7 -6.5 -7.6 -5.8 -8.7 -6.5 -7.6 -12.7 -13.1 -12.4 -13.5 -17.8 -1	-5 -9 -9 -7 -7 -3 -3 -2 -2 -100 -5 -5 -11 -12 -3 -3 -15 -141 -188 -4 -4 -6 -6 -8 -8 -15 -144 -166 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -
horeeper (March) (More of March) (More	763 81.598 70.531 46.6867 30.107 2.203 4.313 94.541 936 3.022 5.994 140.8 106.8 230.1 91.8 9.5 12.6 23.0 111.8 9.5 12.6 23.0 14.5 11.8 9.5 12.6 12.6 12.6 12.6 12.6 12.6 12.6 12.6	0.4 1.2 1.1 0.1 1.6 0.8 0.0 0.9 0.7 0.0 0.7 1.2 1.2 1.2 1.3 1.9 1.3 1.8 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	0.99 3.3 1.6 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1	-10.0 -10.0	-5 -9 -9 -7 -7 -3 -2 -2 -100 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6
honorega (Hazal) Medical (Medical) Medical (Medic	763 81.598 70.531 46.585 30.147 30.147 30.147 30.223 4.203 4	0.4 1.2 1.1 0.1 1.6 0.8 0.0 0.9 0.7 0.0 0.7 1.2 1.2 1.2 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	0.99 3.3 1.6 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1	-10.0 -18.5	-5 -9 -9 -7 -3 -3 -2 -2 -100 -5 -5 -14 -15 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6
honorega (Hazal) Medical (Medical) Medical (Medic	763 81.598 70,5316 46.46 75,147 75,14	0.4 1.2 1.1 0.1 1.6 0.8 0.0 0.9 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.99 3.3 1.6 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1	-10.0 -10.0	-5 -9 -9 -7 -7 -7 -7 -14 -16 -6 -6 -6 -4 -14 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7
honespet (March) Medical (March) Michael (Ma	763 81.599 70.231 61.599 70.231 61.599 70.231 61.50	0.4 1.2 1.1 0.1 1.6 0.8 0.0 0.9 0.7 1.2 0.7 1.6 1.6 1.5 1.3 1.8 1.5 1.3 1.8 1.5 2.3 1.8 1.9 2.1 2.2 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0	0.9	-10.0 -10.0	-5 -9 -9 -7 -3 -3 -2 -2 -100 -5 -5 -110 -166 -5 -1 -124 -186 -5 -144 -186 -6 -6 -144 -186 -6 -6 -144 -186 -144 -186 -186 -186 -186 -186 -186 -1
thorough (March) Modern (Marc	763 11.598 91.59	0.4 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	0.99 3.3 3.6 4.1 4.1 4.5 5.1 4.1 1.8 4.1 1.8 1.9 4.0 0.9 4.0 0.8 0.8 6.6 0.8 6.6 0.8 6.7 1.1 0.9 1.0 0.9 1.0 0.9 1.0 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0	-10.0 1-1	-5 -9 -9 -7 -7 -3 -3 -2 -2 -100 -5 -5 -1 -12 -3 -3 -13 -15 -14 -14 -16 -6 -6 -14 -1 -16 -6 -14 -7 -18 -18 -17 -18 -18 -18 -18 -18 -18 -18 -18 -18 -18
Interespect (March) Medical	763 91.591 91.592 91.592 91.593 91.59	0.4 1.2 1.2 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2	0.99 3.3 1.6 4.1 2.5 4.1 1.8 4.1 1.8 1.8 1.9 4.0 0.9 4.0 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.9 0.9 0.8 0.8 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	-10.0 (18.5) (18	-5 -9 -9 -7 -7 -3 -3 -2 -2 -100 -5 -1 -1 -12 -3 -3 -100 -13 -1 -13 -1 -14 -16 -6 -6 -14 -1 -16 -14 -16 -14 -1 -16 -14 -1 -18 -1 -14 -1 -1 -18 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1
Interespect (March) Medical (March) Medical (March) Medical (March) Micro 1 (Oransia) Micro 1 (Oran	763 101.591 40	0.4 1.2 1.1 1.0 1.0	0.9	-10.0 1-1	-5 -9 -9 -7 -7 -3 -3 -2 -2 -100 -6 -5 -1 -1 -12 -3 -3 -15 -41 -1 -12 -5 -5 -1 -1 -12 -2 -2 -3 -15 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1
Illicorego (Marcillo (Marc	763 91.591 91.59	0.4 1.2 1.2 1.1 1.6 1.6 0.8 0.0 0.0 0.9 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	0.9	-10.0 1-1	-5 -9 -7 -7 -3 -3 -2 -2 -100 -5 -5 -9 -9 -7 -7 -100 -5 -5 -1 -1 -12 -3 -3 -3 -15 -4 -11 -12 -9 -6 -6 -6 -6 -14 -16 -6 -6 -14 -17 -18 -18 -18 -18 -18 -18 -18 -18 -18 -18
honorega (Filed) (Monta) (Mon	763 91.591 91.592 91.59	0.4 1.2 1.2 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2	0.9 3.3 1.6 1.2 1.2 1.4 1.4 1.2 1.2 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4	-10.0 1-1	-5 -9 -7 -7 -3 -2 -2 -10 -5 -5 -1 -12 -3 -3 -15 -5 -14 -14 -18 -9 -6 -6 -6 -14 -15 -14 -16 -6 -6 -14 -17 -7 -18 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17
Illiconega (Mazel Medical Mazel Mazel Medical Medica	763 101.591 40	0.4 1.2 1.2 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2	0.9 3.3 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	-10.0 1-1	-5 -9 -7 -7 -3 -2 -2 -10 -6 -6 -8 -4 -4 -16 -6 -6 -6 -14 -4 -2 -2 -3 -15 -5 -5 -1 -6 -6 -14 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1
Illiconego (Mazello Meson (Mazello M	765 9 11.591 11.502 11.	0.4 1.2 1.2 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2	0.9 3.3 1.6 5.3 1.6 5.2 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	-10.0 1-1	-5 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9
Illiconego (Marco) Illiconego (Marco) MACELEM Largue ** Pricked MACELEM Largue ** MACELEM Largue ** MACELEM Largue ** Sharquis Largue ** S	763 91.591 91.59	0.4 1.2 1.1 1.6 0.1 1.	0.9	-10.0 1-1	-5 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9
honorega (Files) (Monta) (Mon	763 01.593 01.595 01.59	0.4 1.2 1.1.6 0.0 0.1 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1	0.9	-10.0 1-1	-5 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9
honespet (March More of March More	763 101.591 40	0.4 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	0.9	-10.0 -10.0	-5 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9
Interespect (March) Medical Control (March) Medical Control (March) Medical Control (March) Micro 1 Of Control (March) Mic	763 9 1.598 9	0.4 (1.2 (1.2 (1.2 (1.2 (1.2 (1.2 (1.2 (1.2	0.99 1.6 1.6 1.6 1.6 1.7 1.8 1.1 1.8 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9	-10.0 1-10.1 1-1	-5 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9
Incorage March Inco	763 91.591 91.592 91.59	0.4 (1.2 (1.1 (1.1 (1.1 (1.1 (1.1 (1.1 (1.1	0.9	-10.0 1-10.5 1-1	-5 -9 -9 -7 -7 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9
Illiconego Read Illiconego R	763 91.591 91.59	0.4 (1.2 (1.2 (1.2 (1.2 (1.2 (1.2 (1.2 (1.2	0.9	-10.0 1-10.5 1-1	-5 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9 -9
Incorage March	763 91.591 91.592 91.59	0.4 1.2 1.3 1.3 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	0.93 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	-10.0 1-1	-5 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1





Developed Markets US (2-yr) US GER (2-yr)		anges in t	·pl	Marianta	YTD
US		-1.0	Week	MO IILII	
GER (Corr)	2.55 2.92	-1.8	5.6 -2.9	-3 -18	63 45
Germany	-0.62 0.40	0.6 -2.2	3.3	-4 -20	-1 -6
France Spain	0.73 1.30	-3.3 -5.4	-8.4 -17.5	-11 -12	-9 -32
Italy Portugal	2.61 1.82	-13.2 -9.5	-52.6 -23.6	49	51 -19
Greece	4.50	-9.7	-20.6	13	39
Japan (2-yr) Japan	-0.13 0.04	-0.1 -0.9	-1.0 -1.9	-1	-1
Emerging Markets Brazil	12.03	Daily -27.9	Weekly 39.1	Monthly 184	178
Chile	4.60	-27.9 0.2	39.1 4.5	10	9
Colombia Mexico	6.63 7.99	4.6 4.0	5.8 15.8	24	19 42
Peru Poland	5.40 3.25	5.0 2.9	7.2 -6.2	25 -2	53 -6
Russia	7.84	15.9	20.4	37	21
Turkey India	15.64 7.89	0.0 -5.4	115.0 -5.6	151 -1	428 51
Indonesia Country r	7.30	0.0 (es in bp)	0.0	8	100
Developed Markets	level	Daily	Weeldy	Monthly	YTD
10-yr sovereign spread vs Germany France	33	-1.1	-3.9	9	4
Italy	220	-11.0	-48.1	69	57
Portugal Spain	142 89	-7.3 -3.2	-19.1 -13.0	22 9	-13 -26
2-yr sovereign spread vs Germany					
France	12 128	0.0 -12.2	-3.0 -107.3	1 62	-5 91
Italy Portugal	49 39	-12.2 -3.1	48.2	-14	-18
Spain Emerging Markets	level	-4.2 Daily	-4.5 Weeldy	11 Monthly	12 YTD
5-yr sovereign CDS * Brazil	269	8.5	14	78	109
Chile	57	1.5	0	0	8
Colombia	127	5.0	7	15	22
Argentina Mexico	410 149	28.8	53 0	30 26	172 42
Peru	90	2.2	-41	5	18
Polend Russia	68 140	-0.4 -1.1	8	14 6	20 23
Turkey China	300 55	-2.2 -0.6	32 0	41	135 5
India	88	0.5	0	-4 5	19
Indonesia	127 isk indicators	-0.3	2	7	42
Volatilty indicators (change in pp)	level	Daily	Weekly	Monthly	YTD
VIX VSTOXX	13 12	0.4	0 -3	-4	-1
EM EFT volatility Index	18	0.3	0	0	2
Dollar/euro volatility EM FX volatility index	7 10	-0.2 0.1	0	0	1 2
	190	1.8	2	11	13
Credit spread (BAA) (change in bps) US bonds volatility index Inflation expectations (%)	52 level	-1.3 Daily	-7 Weekly	-3 Monthly	3 YTD
US Inflation expectations (5Y5Y)	2.44		0	-2	12
EZ Inflation expectations (5Y5Y) Banking Sy CDS (bps) *	1.73 level	Daily	-1 Weekly	0 Monthly	-1 YTD
US	54	-1.1	-4	2	12
EZ UK	86 52	·5.7	-13 -3	31 10	47 11
Large Spanish	77	-5.7	-15	28	41
Medium Spanish	100	4.3 Daily	2 Weekly	29 Monthly	25 YTD
US Non-financial	144	4.1	-4	2	12
EZ Non-financial UK Non-financial	79 107	-5.7 -1.5	-13 0	31	47 14
Interbank m	arkets (%, ch	inges in b	p)		
EONIA Index	-0.36	Daily	Weeldy	Monthly	YTD
Euribor 3m Euribor 12 m	-0.32	0	0	1	1
Euribor 12 m Libor 3 m	-0.18 2.33	-1	0	1	64
Ubor 12m	2.77	o	2	2	66
	ck markets (
Main indices S&P500	2,768	Daily	Weekly -0.4	Monthly 1.7	YTD
Dow Jones	24,927	-0.5 -1.0	-1.5	0.6	3 0
Nikkei FTSE 100	22.852 7.649	0.5 -1.5	0.7	0.6	0
				4.1	
EuroStoxx 50	3.508	-0.5	1.8	4.5	1
EuroStoxx 50 IBEX	3,508 9,870	-0.5 -0.9	1.8	-2.4	-2
EuroStoxx 50 IBEX DAX CAC	3,508 9,870 13,019 5,508	-0.5 -0.9 -0.7 -0.4	1.8 1.3 2.0 1.1	-2.4 0.2 -1.1	-2 1 4
EuroStoxx 50 IBEX DAX CAC MIB ASS Athens	3,508 9,870 13,019 5,508 22,242 763	-0.5 -0.9 -0.7 -0.4 -1.1	1.8 1.3 2.0 1.1 4.2	-2.4 0.2 -1.1 -6.3	-2 1 4 2
EuroStoxx 50 IBEX DAX CAC MIB ASE Athens MSCI Latam*	3,508 9,870 13,019 5,508 22,242 763 81,598	-0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4	1.8 1.3 2.0 1.1 4.2 -1.2 -0.9	-2.4 0.2 -1.1 -6.3 -3.1 -10.0	-2 1 4 2 -7 -5
EuroStoxx 50 IBEX DAX CAC MIB ASS Athens	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531	-0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2	1.8 1.3 2.0 1.1 4.2	2.4 0.2 4.1 6.3 3.1	-2 1 4 2
Euro Stoxo S 0 IBIEX D AX C AC MIB ASE Athens MSCI Latam* Iboverpas (Brazil) Mesbol (Mesico) Mesval (Arcentrina)	3.508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -1.1 -0.1	1.8 1.3 2.0 1.1 4.2 -1.2 -0.9 -3.3 1.6 -4.1	-2.4 0.2 -1.1 -6.3 -3.1 -10.0 -18.5 0.6 4.8	-2 1 4 2 -7 -5
Euro Stox S O IBIX D AX CAC MIB ASE Athens MSC Latam* Iboverpa (Brazi) Meval (Argentina) Meval (Argentina) Merval (Argentina)	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -1.1 -0.1 -0.1 -0.1	1.8 1.3 2.0 1.1 4.2 -1.2 -0.9 -3.3 1.6 -4.1 -2.5	-2.4 0.2 -1.1 -6.3 -3.1 -10.0 -18.5 0.6	-2 1 4 2 -7 -5 -9
Euro Sicoxis S G IBEX DAX CAC MB MSC Latann* IbDovepa (Brazil) Mebbol (Mexico)	3.508 9.870 13.019 5.508 22.242 763 81.598 70,531 46,686 30,147 5.260 2.203 4,313	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -1.1 -0.1 -0.1 -1.6 -0.8	1.8 1.3 2.0 1.1 4.2 1.2 0.9 3.3 1.6 4.1 2.5 -2.1 1.8	2.4 0.2 4.1 6.3 3.1 40.0 4.8 4.0 3.2 5.2	-2 1 4 2 -7 -5 -9 -7 -3 -2 -10 5
Euro 98 oos 50 IBON NO N	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -1.1 -0.1 -0.1 -0.1 -0.6 -0.8 -0.0 -0.9	1.8 1.3 2.0 1.1 4.2 1.2 -0.9 -3.3 1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8	2.4 0.2 4.1 6.3 3.1 40.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 0.1	-2 1 4 2 -7 -5 -9 -7 -3 -2 -10 5 -20 2
ExeroBoox 50 EEX X DAX CAG ASE Abrons MSC Lature* Hooveraga (Brazil) Meeval (Merganitra) Meeval (Merganitr	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 3,022	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -1.1 -0.1 -0.1 -0.6 -0.8 -0.0 -0.9 -0.7	1.8 1.3 2.0 1.1 4.2 1.2 1.9 3.3 1.6 4.1 2.5 2.1 1.8 1.4 1.8	2.4 0.2 4.1 6.3 3.1 40.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 0.1	-2 1 4 2 -7 -5 -9 -7 -3 -2 -10 5 -20 2 -10
Exercision 50 EEX X DAX DAX CAC Selection 50 Medical Exercision 50 Medical Exercisio	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 3,022 5,994	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -1.1 -0.1 -1.6 -0.8 -0.0 -0.9 -0.7 -0.0 -0.0	1.8 1.3 2.0 1.1 4.2 -1.2 -0.9 -3.3 1.6 4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9	2.4 0.2 1.1 6.3 3.1 10.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 0.1 4.7 2.7	-2 1 4 2 -7 -5 -9 -7 -3 -2 -10 5 -20 2
Live Geosco 50 IBICX DXX DXX DXX DXX GX G	3,508 9,508 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 94,541 3,022 5,994 1,008 1,0	0.5 -0.9 -0.7 -0.4 -1.1 -0.4 -1.2 -1.1 -0.1 -1.6 -0.8 -0.0 -0.9 -0.7 -0.0 -0.0 -0.0 -0.0 -0.0	1.8 1.3 2.0 1.1 4.2 1.2 -0.9 -3.3 1.6 4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9 Weekly -3.1	2.4 0.2 1.1 6.3 3.1 10.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 0.1 4.7 2.7 Monthly 6.6	-2 1 4 2 -7 -5 -9 -7 -3 -2 -10 5 -20 2 -10 -6 -YTD
Litera Geosco 10 IIISC DAX DAX ASE Affirm ASE Affirm MASE Latera* Illowepus (Read) Meestal (Meestal)	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 4,313 94,541 936 3,022 5,994 140,8 106,8	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -1.1 -0.1 -1.6 -0.8 -0.0 -0.9 -0.7 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0	1.8 1.3 2.0 1.1 4.2 -1.2 -0.9 -3.3 1.6 -4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9 Weekly -3.1 -3.9 -4.0	-2.4 0.2 -1.1 -6.3 -3.1 -10.0 -18.5 0.6 -4.8 -4.0 -3.2 -5.2 -7.5 -0.1 -4.7 -2.7 	-2 1 4 2 -7 -5 -9 -7 -3 -2 -10 -5 -20 2 -10 -6 YTD -5 -1 -12
Litera Geosco 10 IIISC DAX DAX ASE Affirm ASE Affirm MASE Latera* Illowepus (Read) Meestal (Meestal)	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 3,022 5,994 level 140,8 65,7 29,0	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -1.1 -0.1 -0.1 -0.8 -0.8 -0.0 -0.9 -0.7 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0	1.8 1.3 2.0 1.1 4.2 1.2 1.9 9 -3.3 1.6 4.1 2.5 -2.1 1.8 1.5 1.9 Weekly -3.1 -3.9 4.0 -3.3	2.4 0.2 1.1 6.3 3.1 10.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 0.1 4.7 2.7 Monthly 6.6 5.8 8.7 6.5	-2 1 4 2 -7 -5 -9 -7 -3 -2 -10 -5 -20 2 -10 -6 -7 -1 -12 -3
Live Geox 60 IBICK DAY AND AND AND AND AND AND AND	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 3,022 5,994 100.8 106.8 65.7 29.0 50.8	0.5 -0.9 -0.7 -0.4 -1.1 -0.0 -1.2 -1.1 -0.1 -1.6 -0.8 -0.0 -0.9 -0.7 -0.0 -0.9 -0.7 -1.2 -1.2 -1.6 -1.0 -1.6 -1.0 -1.5	1.8 1.3 2.0 1.1 4.2 1.2 1.9 9 -3.3 1.6 4.1 -2.5 -2.1 -1.8 -1.4 -1.8 1.5 -1.9 Weekly -3.1 -3.9 -4.0 -3.3 -2.2 -1.4	2.4 0.2 1.1 6.3 3.1 10.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 0.1 4.7 2.7 Monthly 6.6 8.7 6.5 8.7	-2 1 4 2 -7 -5 -9 -7 -3 -2 -10 5 -20 2 -10 -6 YTD -5 -1 -12 -3 -3 -10
Litera Gross 16 IBICK DAY DAY ASE Affines ASE Affines MSC Latera* Illicorega (Read) Mercal (Wester) Mercal (Wester) Mercal (Wester) Microl (Mercal)	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 3,022 5,994 100.8 106.8 65.7 29.0 106.8 230.1	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -1.1 -0.1 -1.6 -0.8 -0.9 -0.7 -0.0 -0.9 -1.2 -1.2 -1.6 -1.0 -1.5	1.8 1.3 2.0 1.1 4.2 -1.2 -0.9 -3.3 1.6 4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9 Weekly -3.1 -3.9 -4.0 -3.3 -2.2 -1.4 0.9	2.4 0.2 1.1 6.3 3.1 10.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 0.1 4.7 2.7 2.7 6.6 5.8 8.7 6.5 7.6 4.5 12.7	-2 1 4 2 -7 -5 -9 -7 -7 -3 -2 -10 5 -20 2 -10 -6 -5 -1 -1 -12 -3 -3 -3 -12 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10
Clare Glosco 50 (ISC) CAS A STATE OF THE S	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 936 106,8 106	-0.5 -0.9 -0.7 -0.4 -1.1 -0.4 -1.2 -0.1 -0.1 -0.1 -0.1 -0.8 -0.8 -0.9 -0.7 -0.0 -0.9 -0.7 -1.2 -1.2 -1.2 -1.2 -1.5 -1.5 -1.5 -1.5 -1.5 -1.5 -1.5 -1.5	1.8 1.3 2.0 1.1 4.2 -1.2 -0.9 -3.3 1.6 4.1 -2.5 -2.1 -1.8 -1.4 -1.8 -1.5 -1.9 Weekly -3.1 -3.9 -4.0 -3.3 -2.2 -1.4 0.9 0.8	2.4 0.2 1.1 6.3 3.1 10.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 0.1 4.7 2.7 Monthly 6.6 4.8 8.7 6.5 7.6 12.7 12.7	-2 1 4 2 -7 -5 -9 -7 -3 -2 -2 -10 -6 -7 -5 -20 -2 -10 -6 -5 -1 -12 -3 -3 -12 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10
Lare Glosco 10 LICK CASC ASS A Phone ASS	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 4,313 94,541 936 3,022 5,994 1,40.8 106.8 65,7 29,0 50.8 230.1 91.8 54,1 11.8 9,5	0.5 -0.9 -0.7 -0.4 -1.1 -2.0 -0.4 -1.2 -0.1 -0.1 -0.6 -0.8 -0.0 -0.9 -0.7 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0	1.8 1.3 2.0 1.1 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.3 3.3 1.6 4.1 4.8 4.1 4.8 4.1 4.8 4.0 4.0 4.0 4.0 4.0 6.5 6.6 6.8	2.4 0.2 1.1 6.3 3.1 10.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 0.1 4.7 2.7 Monthly 6.6 5.8 4.5 7.6 5.7 6.5 7.6 5.7 6.5 7.1 2.7 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	-2 1 4 2 -7 -5 -9 -7 -3 -3 -2 -2 -10 -6 -7 -10 -6 -7 -10 -6 -7 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10
Lare Glosco 10 IDICA DO AND AND AND AND AND AND AND AND	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 94,541 106,8 65,7 29,0 50,8 106,8 65,7 11,8 9,5 11,8 9,5 11,8 9,5 11,8 9,5 11,8 9,5 11,8 9,5 11,8 9,5 11,8 9,5 11,8 11,8 11,8 11,8 11,8 11,8 11,8 11	0.5 0.9 0.7 0.4 1.1 1.2 2.0 0.4 1.2 1.1 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0	1.8 1.3 2.0 1.1 4.2 2.0 1.2 0.9 3.3 3.1.6 4.1 1.8 4.1 1.8 1.9 Weekly 4.0 0.9 0.8 0.8 0.8	2.4 0.2 1.1 6.3 3.1 10.0 18.5 0.6 4.8 4.0 3.2 5.2 7.5 2.7 2.7 2.7 2.7 4.7 2.7 4.7 2.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4	-2 1 4 2 -7 -5 -9 -9 -7 -7 -3 -3 -2 -2 -10 -6 -5 -1 -10 -6 -11 -12 -3 -3 -10 -16 -16 -16 -16 -16 -16 -16 -16 -16 -16
Law Glosso 50 IIISC DAY AND AND AND AND AND AND AND	3,508 9,870 13,019 5,508 22,242 763 81,598 70,531 46,686 30,147 5,260 2,203 4,313 94,541 94,541 106,8 65,7 29,0 50,8 106,8 65,7 29,0 51,8 11,8 9,5 11,8 11,8 11,8 11,8 11,8 11,8 11,8 11	0.5 0.9 0.7 0.4 1.1 0.1 1.1 0.1 1.6 0.8 0.9 0.7 1.2 0.7 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	1.8 1.3 2.0 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 6.3 3.1 10.0 18.5 5.2 5.2 5.2 7.5 0.1 4.7 2.7 Monthly 6.5 6.5 6.5 6.5 6.5 6.5 6.5 7.6 6.5 6.5 7.6 7.6 7.7 7.7 7.7 7.7 7.7 7.7 7.7 7.7	-2 1 4 2 -7 -5 -9 -7 -3 -2 -2 -10 -6 -8 YTD -5 -1 -1 -12 -3 -3 -3 -10 -16 -16 -16 -17 -17 -17 -18 -18 -18 -18 -18 -18 -18 -18 -18 -18
Larva Geora 10 LICK CAL ASS A Share A Share ASS A Share	3,508 9,870 13,019 5,508 22,242 70,531 46,686 30,147 5,260 2,203 4,313 94,541 106.8 65,7 29,0 140.8 106.8 65,7 29,0 140.8 150.8 150.8 160.8	0.5 0.9 0.7 0.4 1.1 2.0 0.4 1.2 1.1 0.1 0.1 0.1 0.1 0.0 0.9 0.7 0.0 0.8 1.2 0.7 1.2 1.2 1.1 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3	1.8 1.3 2.0 1.1 1.2 2.0 1.1 1.2 2.0 1.1 1.2 2.0 1.1 1.2 2.5 1.1 1.8 1.1 1.5 1.9 1.0 2.1 1.8 1.5 1.9 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	2.4 0.2 1.1 6.3 3.1 -10.0 0.6 4.8 4.0 0.6 4.8 4.0 2.5 2.7 2.7 2.7 Monthly 6.6 4.7 6.6 4.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6	-2 1 4 2 -7 -5 -9 -9 -7 -3 -2 -2 -10 -6 -5 -1 -12 -3 -3 -3 -3 -3 -10 -16 -13 -14 -18 -18 -18 -18 -18 -18 -18 -18 -18 -18
Law Glosco 10 IDICA DATE ASE Affines ASE	3,508 9,870 13,019 5,508 22,242 70,531 46,686 30,147 5,260 2,203 4,313 94,541 106,8 106	0.5 0.9 0.7 0.4 1.1 2.0 0.4 1.2 1.1 0.1 0.1 0.1 0.1 0.0 0.9 0.7 1.2 0.0 0.9 0.7 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1	1.8 1.3 2.0 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 6.3 3.1 10.0 6.4 4.0 3.2 7.5 5.2 7.5 2.7 2.7 2.7 2.7 4.7 2.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4	-2 1 4 2 -7 -7 -5 -9 -9 -7 -7 -3 -2 -2 -10 -6 -5 -1 -12 -3 -3 -3 -3 -10 -16 -16 -16 -16 -16 -16 -16 -16 -16 -16
Law Glosco 50 IBINE AND AND AND AND AND AND AND A	3,508 9,870 13,019 5,508 22,242 73,019 16,686 30,147 5,260 2,203 4,313 94,541 93,022 5,994 140,8 165,7 29,0 50,8 25,7 29,0 50,8 20,1 11,8 9,5 12,6 12,6 13,1 14,8 16,7 16,8 16,7 16,8 16,7 16,8 16,7 16,9 16	0.5 0.9 0.7 0.4 1.1 1.2 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0	1.8 1.3 2.0 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 6.3 3.1 10.0 18.5 0.6 4.8 4.0 3.2 7.5 0.1 4.7 2.7 2.7 6.5 8.7 6.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4	-2 1 4 2 -7 -7 -5 -9 -7 -7 -7 -7 -7 -10 -5 -20 -2 -10 -6 -5 -1 -12 -3 -3 -10 -16 -13 -13 -16 -16 -16 -16 -16 -16 -16 -16 -16 -16
Larva Glosco 50 LISC CANADA C	3,508 9,870 13,019 5,508 22,242 70,531 46,686 70,531 46,686 30,187 5,203 4,313 94,541 106,8 106,	0.5 0.9 0.7 0.4 1.1 2.0 0.4 1.2 1.1 0.1 0.1 1.6 0.8 0.0 0.9 0.7 0.0 0.0 1.2 1.2 1.2 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3	1.8 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.2 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.3 1.6 1.6 1.1 1.8 1.1 1.5 1.9 1.0 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3	2.4 0.2 1.1 6.3 3.1 -10.0 0.6 18.5 0.6 4.0 9.2 5.2 7.5 0.1 4.7 2.7 2.7 8.8 7.5 6.5 6.5 6.5 12.1 12.4 13.5 14.1 15.6 16.1 16.1 16.1 16.1 16.1 16.1 16	2 1 4 2 7 7 7 3 3 2 2 10 5 5 9 7 7 3 2 2 10 6 6 11 12 3 3 10 16 16 17 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18
Clare Glosco 50 (IDC) CAS A Manus ASS A Almans ASS A Almans ASS A Almans MASC Latture* Incorposal (Res) MASC Latture* Incorposal (Res) MASC Latture* MASC Lattur	3,508 9,870 13,019 5,508 22,242 75,508 81,598 70,531 46,686 30,147 5,200 4,313 94,541 100.8 100.	0.5 0.9 0.7 0.4 1.1 2.0 0.4 1.1 0.1 0.1 0.1 0.1 0.7 0.0 0.9 0.7 0.0 0.7 0.0 1.2 1.2 1.3 1.9 1.1 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	1.8 1.3 2.0 1.1 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 6.3 3.1 1.0.0 6.4 8.8 6.0 6.4 6.6 6.6 6.6 6.6 6.6 6.6 6.7 6.6 6.6 6.7 6.6 6.6	-2 1 4 2 -7 -7 -5 -9 -7 -7 -7 -3 -2 -2 -10 -5 -5 -1 -10 -6 -6 -7 -12 -3 -3 -10 -16 -13 -15 -16 -16 -16 -16 -16 -16 -16 -16 -16 -16
Larva Geora 50 LISC CAC CAC CAC CAC CAC CAC CAC CA	3.508 9,870 13,019 9,870 13,019 9,870 13,019 9,870 13,019 9,870 13,019 14,019 1	0.5 0.9 0.9 0.7 0.4 1.1 1.2 0.1 1.1 1.6 0.8 0.0 0.9 0.7 0.7 0.0 0.9 1.2 1.2 1.2 1.2 1.3 1.9 1.5 1.5 1.3 1.9 1.5 1.5 1.3 1.9 1.5 1.5 1.3 1.9 1.5 1.5 1.3 1.9 1.5 1.5 1.3 1.9 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	1.8 2.0 1.1 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 10.0 6.3 3.1 10.0 18.5 0.5 4.8 4.0 3.2 5.2 7.5 5.0 4.7 2.7 7.5 6.6 4.5 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7	2 1 4 2 7 7 5 9 9 7 7 3 2 2 10 6 5 1 1 12 3 3 3 10 16 16 17 18 17 18 18 19 19 19 19 19 19 19 19 19 19 19 19 19
Clare Glosco 50 Click	3.508 9.870 13.019 9.870 13.019 9.870 13.019 9.870 13.019 14.019	0.5 0.9 0.9 0.7 0.4 1.1 1.1 1.6 0.8 0.0 0.9 0.7 1.2 0.7 0.0 0.9 1.2 1.2 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	1.8 2.0 1.1 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 1.6 3.1 1.0 1.0 1.8 5.2 5.2 5.2 7.5 6.6 6.6 6.6 6.6 6.6 6.7 6.7 6.7 6.7 6.7	2 1 1 4 2 7 7 5 5 9 9 7 7 3 3 2 2 100 5 5 1 1 12 2 3 3 100 6 6 13 3 15 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Live Glosco 50 IBISC DAY MISS	3.508 9,870 13,019 9,870 13,019 9,870 13,019 9,870 13,019 9,870 13,019 14,019 1	0.5 0.9 0.9 0.7 0.6 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	1.8 2.0 2.1 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 1.0 6.3 3.1 1.0 1.0 6.3 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0	2 1 1 4 2 7 7 5 5 9 9 7 7 3 3 2 2 100 5 5 1 1 12 2 3 3 100 6 6 13 3 15 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Lare Glosco 10 Life Committee Commi	3.508 9.870 13.019 9.870 13.019 9.870 13.019 9.870 13.019	0.5 0.9 0.9 0.7 0.6 0.5 0.9 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.9 0.7 0.7 0.6 0.9 0.9 0.7 0.7 0.6 0.9 0.9 0.7 0.7 0.7 0.6 0.9 0.9 0.9 0.9 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	1.8 2.0 1.1 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 1.0 10.0 18.5 6.2 7.5 6.7 6.7 6.8 8.7 7.2 7.7 7.7 8.7 7.7 8.7 7.7 8.7 7.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1	-2 1 4 2 7 -7 -5 -9 -7 -7 -3 -2 -2 -10 -5 -1 -12 -3 -3 -3 -10 -16 -16 -13 -15 -14 -14 -16 -16 -16 -16 -16 -16 -16 -16 -16 -16
Law Glosco 50 ISSN CALL STATE OF THE STATE	3.5008 9.870 9.770 9.870 9.870 9.870 9.870 9.870 9.870 9.870 9.870 9.870 9.870 9.870 9.870 9.870 9.870 9.770 9.770 9.770 9.770 9.770 9.770 9.770	0.5 0.9 0.9 0.7 0.6 0.5 0.9 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.7 0.7 0.6 0.9 0.9 0.7 0.7 0.6 0.9 0.9 0.7 0.7 0.6 0.9 0.9 0.7 0.7 0.7 0.6 0.9 0.9 0.9 0.9 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	1.8 2.0 1.1 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 1.0 10.0 18.5 6.2 7.5 6.7 6.7 6.8 8.7 7.2 7.7 7.7 8.7 7.7 8.7 7.7 8.7 7.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1	22 1 1 4 2 2 7 7 5 9 9 7 7 3 3 2 2 2 100 5 5 200 0 1 5 1 1 1 1 2 2 3 3 3 1 5 5 1 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Lincollones 50 IESC AND AND AND AND AND AND AND AN	3.508 9.870 13.0108 9.870 13.0108 9.870 13.0108 9.870 13.0108 9.870 13.018 9.018 9.	0.5 0.9 0.9 0.7 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	1.8 1.3 2.0 1.1 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	2.4 0.2 1.1 1.6 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	-2 1 4 4 2 -2 7 -5 9 9 -7 7 3 -2 2 10 6 5 -1 12 -3 3 -1 10 16 -1 3 15 -1 14 18 9 9 6 6 -6 8 4 4 8 15 -1 14 16 6 6 6 14 17 18 18 17 18 18 17 18 18 17 18 18 18 19 19 10 10 10 10 10 10 10 10 10 10 10 10 10
Litera Book S 10 LISC A Many S 10 LIST A MANY	3.5008 9.8709 9.	0.5 0.9 0.9 0.7 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	1.8 1.3 2.0 1.1 1.1 1.2 2.0 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	2.4 0.2 -1.1 -6.3 -3.1 -10.0 -18.5 -6.2 -7.5 -6.4 -6.3 -7.5 -6.5 -6.7 -6.5 -7.6 -6.5 -7.6 -6.5 -7.6 -6.5 -7.6 -7.6 -7.6 -7.6 -7.6 -7.6 -7.6 -7.6	21 4 2 2 7 7 5 9 9 7 7 3 2 2 10 0 5 5 11 12 2 3 3 15 10 14 18 8 7 15 14 16 6 6 6 6 14 4 7 18 8 7 18
Lincollones 50 IESC Affords ASS Affords A	3.5008 9.0709 1.5009 1.	0.5 0.9 0.9 0.7 0.0 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	1.8 1.3 2.0 1.1 1.1 1.2 2.0 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.2 2.0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	2.4. 0.21.1. 6.33.110.018.54.03.27.54.03.27.56.56.76.56.76.56.7	21 4 4 2 2 7 7 5 9 9 7 7 3 2 2 0 10 6 6 13 15 14 14 19 6 6 6 6 6 6 14 7 7 18 17 17 18 17 18 17 18 17 18 17 18 17 18 17 18 17 18 17 18 17 18 17 18 18 17 18 18 18 18 18 18 18 18 18 18 18 18 18
Larva George 16 Life Control	3.5008 9.8709 9.	0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	1.8 1.3 2.0 1.1 1.1 1.2 2.5 2.1 1.1 1.2 2.0 1.2 2.0 1.2 2.0 1.2 2.0 1.2 2.0 1.2 2.0 1.2 2.0 1.2 2.0 1.2 2.0 1.2 2.0 1.2 2.0 1.2 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2	2.4 (2.2 (1.1 (1.1 (1.1 (1.1 (1.1 (1.1 (1.1	21 1 4 2 2 7 7 7 14 4 9 16 6 6 6 6 6 6 6 6 6 6 6 6 7 18 9 17 18 9 17 18 9 18 9 18 9 18 9 1
Larva Glosco 16 LIGHT CALL CALL CALL CALL CALL CALL CALL CAL	3.500 9 9,000	0.5 0.9 0.9 0.7 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	1.8 1.3 2.0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	2.4 (2.2 - 1.1 - 1.2 - 1	21 1 4 2 2 2 3 3 155 5 5
Euro-Bosco 10 ECC CAC ASS Afferen ASS Aff	3.5008 9.000	0.5 0.9 0.7 0.9 0.7 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	1.8 1.3 2.0 1.1 1.1 1.2 2.5 5.2 1.1 1.8 1.1 1.5 1.5 2.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1	22.4 0.2 1.1 0.2 1.1 6.3 3.1 1.0 0.6 6.3 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0	21 4 2 2 3 3 10 6 6 6 6 6 6 6 14 7 7 -18 8 17 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18
Larva George 16 Life Control	3.5008 9,000	0.5 0.9 0.7 0.9 0.7 0.9 0.7 0.9 0.9 0.7 0.7 0.9 0.9 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	1.8 1.3 2.0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	224 0.2 1.1 0.2 1.1 6.3 3.1 1.1 6.3 3.1 1.1 6.3 6.4 4.0 6.5 6.4 4.7 7.5 6.5 6.7 6.5 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7	21 4 2 7 7 5 9 7 7 3 2 2 10 0 5 2 2 0 10 6 7 11 2 3 3 10 6 13 15 14 18 9 15 14 14 17 18 17 18 17 18 17 18 17 18 18 18 18 18 18 18 18 18 18 18 18 18
Larva Glosco 50 LIDICA LIDICA ASS A Anness MSG Latture* Liborague (March Liborague) (March MSG Latture* Liborague) (March MSG Latture* Liborague) (March MSG Latture* Liborague) (March MSG Latture* Liborague Lib	3.5008 9.8709 9.	0.5 0.5 0.1 0.5 0.5 0.2 0.1 0.5 0.5 0.2 0.1 0.5 0.2 0.1 0.5 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	1.8 1.3 2.0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	244 0.2 -1.1 -3.3 -3.1 -3.3 -3.1 -3.5 -3.5 -3.5 -3.5 -3.5 -3.5 -3.5 -3.5	21 4 2 7 7 5 9 7 7 3 3 2 10 6 6 11 12 3 3 10 16 6 13 14 18 9 6 6 6 14 17 18 17 14 9 16 16 17 18 17 18 18 18 18 18 18 18 18 18 18 18 18 18
Lare Glosco 50 Life Control C	3.5008 9,100	0.5 0.9 0.9 0.7 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	1.8 1.3 2.0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	244 0.2 1.1 6.3 3.1 6.3 3.1 6.3 3.1 6.3 6.4 4.0 6.8 4.0 6.8 6.8 6.7 6.5 6.8 6.7 6.5 6.8 6.7 6.8 6.8 6.1 6.1 6.1 6.1 6.1 6.1 6.1 6.1 6.1 6.1	21 4 2 2 7 7 5 9 9 7 7 3 2 2 10 0 5 5 5 5 1 1 6 6 1 11 7 7 10 10 1 1 1 1 7 10 10 1 1 1 1
Lare allows 50 Life Control of the	3.5008 9,0709 1,5009 1,	0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	1.8 2.0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	244 0.2 1.1.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3	21 4 2 2 7 7 5 9 9 7 7 7 3 3 2 1 6 5 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Lare Glosco 15 Life Control C	3.5008 9.100	0.5 0.5 0.2 0.1 1.2 1.3 1.5 1.5 1.3 1.5 1.5 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	1.8 1.3 2.0 1.1 1.3 2.0 1.1 1.3 2.0 1.1 1.3 2.0 1.5 2.1 1.4 1.1 1.5 1.5 2.1 1.4 1.5 1.5 2.1 1.4 1.5 1.5 2.1 1.4 1.5 1.5 2.1 1.4 1.5 1.5 2.1 1.4 1.5 1.5 2.1 1.5 1.5 2.1 1.5 1.5 2.1 1.5 1.5 2.1 1.5 1.5 2.1 1.5 1.5 2.1 1.5 1.5 2.1 1.5 1.5 2.1 1.5 2.	244 0.2 1.1.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3	-2
Larva Glosco 16 LISC A CONTROL CONTRO	3.5008 9.00 15.508	0.5 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	1.8 1.3 2.0 1.4 1.4 1.4 1.5 1.5 1.9 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	244 0.2 11.1 10.0 11.0 10.1 10.0 10.0 10.0	21 1 4 2 2 3 3 145 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Larva George 15 Life Control	3.5008 9.100	0.5 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	1.8 1.3 2.0 1.3 1.3 2.0 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	244 0.2 1.1.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3	-2
Larva Bloom 50 LIST A CONTROL	3.5008 9,100	0.5 0.9 0.9 0.7 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	1.8 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1	244 0.2 11.1 10.0 11.0 10.1 10.0 10.0 10.0	21 1 4 2 2 3 3 145 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Larva Glosco 10 LIGHT CALL CALL CALL CALL CALL CALL CALL CAL	3.5008 9,0709 1,5008 9,0709 1,5008 1,	0.5	1.8 2.0 1.1 2.1 1.2 1.1 2.1 1.2 1.1 2.1 1.2 1.1 2.1 2	244 0.2 111 100 0.2 111 100 0.3 30.1 100 0.5 4.8 4.8 4.8 4.7 4.8 6.7 6.5 6.8 6.7 6.5 6.8 6.7 7.6 6.8 6.8 6.7 7.6 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6	21 1 4 2 2 3 3 4 16 6 6 6 14 1 7 18 18 2 2 3 3 15 5 5 1 1 6 5 1 1 7 7 10 2 2 5 1 1 1 7 7 10 7 7 7 10 7 7 7 10 7 7 7 10 7 7 7 10 7 7 7 10 7 7 7 10 7 7 7 10 7 7 7 10 7 7 7 10 7 7 7 10 7 7 7 10 10 7 7 7 10 7 7 10 7 7 10 7 7 10 7 7 10 7 7 10
Larva George 15 Life Control	3.5008 9.8709 9.	0.5 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	1.8 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0	244 0.2 111 100 0.2 111 100 0.6 100 100 100 100 100 100 100 100 100 10	21 1 4 2 2 3 3 2 2 10 5 5 2 2 2 3 3 15 5 5 1 1 6 6 14 17 17 18 17 17 18 17 18 17 18 17 18 18 18 18 18 18 18 18 18 18 18 18 18
Lare Glosco 50 LINC CARLOS CA	3.5008 9,000	0.5	1.8 1.3 2.0 2.0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	244 0.2 111 10.0 0.3 3.1 10.0 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3	21 4 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Larva George 15 Life Control	3.5008 9,0709 1,5009 1,	0.5 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.7 0.9	1.8 1.3 2.0 1.1 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3	244 0.2 3-11 100 3-1 1	21 4 2 2 7 5 5 5 5 1 1 6 6 6 6 6 14 1 1 6 1 1 6 1 1 1 1 1



Fuente: BBVA Research

Fuente: BBVA Research

This document and the information, opinions, estimates and recommendations expressed herein, have been prepared by Banco Bilbao Vizcaya Argentaria, S.A. (hereinafter called "BBVA") to provide its customers with general information regarding the date of issue of the report and are subject to changes without prior notice. BBVA is not liable for giving notice of such changes or for updating the contents hereof

This document and its contents do not constitute an offer, invitation or solicitation to purchase or subscribe to any securities or other instruments, or to undertake or divest investments. Neither shall this document nor its contents form the basis of any contract, commitment or decision of any kind.

Investors who have access to this document should be aware that the securities, instruments or investments to which it refers may not be appropriate for them due to their specific investment goals, financial positions or risk profiles, as these have not been taken into account to prepare this report. Therefore, investors should make their own investment decisions considering the said circumstances and obtaining such specialized advice as may be necessary. The contents of this document are based upon information available to the public that has been obtained from sources considered to be reliable. However, such information has not been independently verified by BBVA and therefore no warranty, either express or implicit, is given regarding its accuracy, integrity or correctness. BBVA accepts no liability of any type for any direct or indirect losses arising from the use of the document or its contents. Investors should note that the past performance of securities or instruments or the historical results of investments do not guarantee future performance.

The market prices of securities or instruments or the results of investments could fluctuate against the interests of investors. Investors should be aware that they could even face a loss of their investment. Transactions in futures, options and securities or high-yield securities can involve high risks and are not appropriate for every investor. Indeed, in the case of some investments, the potential losses may exceed the amount of investment and, in such circumstances; investors may be required to pay more money to support those losses. Thus, before undertaking any transaction with these instruments, investors should be aware of their operation, as well as the rights, liabilities and risks implied by the same and the underlying stocks. Investors should also be aware that secondary markets for the said instruments may be limited or even not exist.

BBVA or any of its affiliates, as well as their respective executives and employees, may have a position in any of the securities or instruments referred to, directly or indirectly, in this document, or in any other related thereto; they may trade for their own account or for third-party account in those securities, provide consulting or other services to the issuer of the aforementioned securities or instruments or to companies related thereto or to their shareholders, executives or employees, or may have interests or perform transactions in those securities or instruments or related investments before or after the publication of this report, to the extent permitted by the applicable law.

BBVA or any of its affiliates' salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to its clients that reflect opinions that are contrary to the opinions expressed herein. Furthermore, BBVA or any of its affiliates' proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. No part of this document may be (i) copied, photocopied or duplicated by any other form or means (ii) redistributed or (iii) quoted, without the prior written consent of BBVA. No part of this report may be copied, conveyed, distributed or furnished to any person or entity in any country (or persons or entities in the same) in which its distribution is prohibited by law. Failure to comply with these restrictions may breach the laws of the relevant jurisdiction.

In the United Kingdom, this document is directed only at persons who (i) have professional experience in matters relating to investments falling within article 19(5) of the financial services and markets act 2000 (financial promotion) order 2005 (as amended, the "financial promotion order"), (ii) are persons falling within article 49(2) (a) to (d) ("high net worth companies, unincorporated associations, etc.") Of the financial promotion order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the financial services and markets act 2000) may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. The remuneration system concerning the analyst/s author/s of this report is based on multiple criteria, including the revenues obtained by BBVA and, indirectly, the results of BBVA Group in the fiscal year, which, in turn, include the results generated by the investment banking business; nevertheless, they do not receive any remuneration based on revenues from any specific transaction in investment banking.

BBVA is not a member of the FINRA and is not subject to the rules of disclosure affecting such members.

"BBVA is subject to the BBVA Group Code of Conduct for Security Market Operations which, among other regulations, includes rules to prevent and avoid conflicts of interests with the ratings given, including information barriers. The BBVA Group Code of Conduct for



Security Market Operations is available for reference at the following web site: www.bbva.com / Corporate Governance".

BBVA is a bank supervised by the Bank of Spain and by Spain's Stock Exchange Commission (CNMV), registered with the Bank of Spain with number 0182.

Fuente: BBVA Research

Fuente: BBVA Research